In a study, the combination of SGLT2 inhibitors with neprilysin inhibitors demonstrated promising results in improving glycemic control and reducing inflammation and oxidative stress, which are key factors in the progression of DKD (Tarun et al., 2024). Here, MME is linked to diabetic kidney disease.